A 34-year-old patient with HIV returns to clinic after being out of care for several years. Previously, they received a regimen of boosted atazanavir with tenofovir DF-emtricitabine, but experienced virologic breakthrough (HIV RNA 2,980 copies/mL). A genotype was performed at the time and showed only a reverse transcriptase M184V mutation.
Which one of the following statements is TRUE regarding the M184V mutation?
Figure 1. Impact of M184V Mutation on Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Stanford University HIV Drug Resistance Database
Illustration: David H. Spach, MD
Sign In or Register Progress Not Saved!
Since you are not signed in, your progress won't be saved.
Since you are not signed in, your progress won't be saved.
Question Last Updated
September 21st, 2023
September 21st, 2023
Steps to Acquire CE for this Question Bank Topic:
1
Answer
Answer all questions
2
Score 80%+
Answer correctly
3
Claim CE
Choose CNE or CME
4
Give Feedback
Complete survey
5